KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine
Annals of Clinical and Translational Neurology · 2023-04 · 10 (4) · 656-663
DOI: 10.1002/acn3.51742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 15.02.2023. Verfasst von Peter Müller und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, 72076, Germany. Hauptthemen laut MEDLINE: Epilepsy, Epilepsy, Generalized. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Deutsche Forschungsgemeinschaft, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Precision medicine for Mendelian epilepsy is rapidly developing. We describe an early infant with severely pharmacoresistant multifocal epilepsy. Exome sequencing revealed the de novo variant p.(Leu296Phe) in the gene KCNA1 , encoding the voltage‐gated K + channel subunit K V 1.1. So far, loss‐of‐function variants in KCNA1 have been associated with episodic ataxia type 1 or epilepsy. Functional studies of the mutated subunit in oocytes revealed a gain‐of‐function caused by a hyperpolarizing shift of voltage dependence. Leu296Phe channels are sensitive to block by 4‐aminopyridine. Clinical use of 4‐aminopyridine was associated with reduced seizure burden, enabled simplification of co‐medication and prevented rehospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, 72076, Germany.
- Division of Neurology and Developmental Neuroscience, Epilepsy and Neurophysiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
- Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
- Division of Genetics, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
- Baylor Genetics, Houston, Texas, USA.
ORCID-Profile: Edward C Cooper
Förderung
- NINDS NIH HHS
- Deutsche Forschungsgemeinschaft
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Müller, P., Takacs, D. S., Hedrich, U. B. S., Coorg, R., Masters, L., Glinton, K. E., Dai, H., Cokley, J. A., Riviello, J. J., Lerche, H., & Cooper, E. C. (2023). KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine. Annals of Clinical and Translational Neurology, 10(4), 656-663. https://doi.org/10.1002/acn3.51742
Vancouver
Müller P, Takacs DS, Hedrich UBS, Coorg R, Masters L, Glinton KE, et al. KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine. Annals of Clinical and Translational Neurology. 2023;10(4):656-663. doi:10.1002/acn3.51742
BibTeX
@article{Mller2023,
author = {Müller, Peter and Takacs, Danielle S and Hedrich, Ulrike B S and Coorg, Rohini and Masters, Laura and Glinton, Kevin E and Dai, Hongzheng and Cokley, Jon A and Riviello, James J and Lerche, Holger and Cooper, Edward C},
title = {KCNA1 gain‐of‐function epileptic encephalopathy treated with 4‐aminopyridine},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
volume = {10},
number = {4},
pages = {656--663},
doi = {10.1002/acn3.51742}
}
EUVIMED